Download PDF
Der Nuklearmediziner 2021; 44(01): 35-41
DOI: 10.1055/a-1293-2162
Lunge

Das metastasierte nichtkleinzellige Lungenkarzinom im Wandel – Einblick in neue therapeutische Strategien zur Behandlung des NSCLC

Changing treatment landscape in metastatic lung cancer – Insight into novel treatment strategies in non-small cell lung cancer
Carolin Lips
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Sebastian Thiel
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Jens Kollmeier
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Torsten Gerriet Blum
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Monica Schäfer
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Susann Stephan-Falkenau
2   MVZ Gewebediagnostik/Pathologie, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Anna Streubel
2   MVZ Gewebediagnostik/Pathologie, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Thomas Mairinger
2   MVZ Gewebediagnostik/Pathologie, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Torsten Bauer
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
,
Daniel Misch
1   Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Das Lungenkarzinom ist weltweit die häufigste Todesursache unter den Krebserkrankungen. [1] In Deutschland erkrankten im Jahr 2016 etwa 21 500 Frauen und 36 000 Männer an bösartigen Tumoren der Lunge, 16 481 Frauen und 29 324 Männer verstarben an dieser Erkrankung. [2] In den letzten Jahren ist die Bedeutung molekularer Testung von Tumorgewebe bei Patienten mit metastasierten nichtkleinzelligen Lungenkarzinom (NSCLC) immer weiter in den Vordergrund gerückt und bestimmt nunmehr unser therapeutisches Handeln. Neue zielgerichtete Therapiestrategien wie die Tyrosinkinase-Inhibitoren und die Immuntherapie rücken immer weiter in den Fokus und haben die Diagnostik und das Management der Erkrankung über die Jahre revolutioniert. Durch den gezielten Einsatz dieser neuen Substanzen hat sich die Prognose des metastasierten NSCLC dramatisch gewandelt. Besonders Patienten mit aktivierenden Treibermutationen haben von den Entwicklungen der letzten Jahre enorm profitiert. Am Beispiel der EGFR-Mutation und der ALK- Fusion sehen wir Überlebensdaten, die noch vor wenigen Jahren utopisch erschienen.

Abstract

Lung cancer is the leading cause of cancer deaths globally. [1] In Germany, lung cancer occurred in approximately 21 500 women and 36.000 men in the year of 2016, 16 481 women and 29 324 men died of this disease. [2] Over the last couple of years, molecular characterization of tumor tissue in patients with non-small cell lung cancer (NSCLC) has become a vital part of our clinical routine and serves as a guide to treatment. Novel treatment selection, from tyrosin kinase-inhibitors to immunotherapy, is more available than ever and revolutionized our management of this disease. Through the targeted use of these new substances prognosis for patients with metastatic NSCLC has dramatically improved. Especially patients with an activating mutation such as EGFR and ALK have shown incredible survival data and have benefited from these advances over the last years.

Schlüsselwörter

Lungenkarzinom - Treibermutation - zielgerichtete Therapie - Immunonkologie

Keywords

lung cancer - activating mutation - targeted therapy - immuno oncology


Publication History

Article published online:
08 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394
    CrossrefPubMedGoogle Scholar
  • 2 Zentrum für Krebsregister Daten RKI Stand 2016. Verfügbar unter: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Lungenkrebs/lungenkrebs_node.html
    PubMedGoogle Scholar
  • 3 Schiller JH, Harrington D, Belani CP. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 10.01.2002; 346: 92-98
    CrossrefPubMedGoogle Scholar
  • 4 https://www.nngm.de/
    PubMed
  • 5 Lindeman N, Cagle P, Aisner D. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018; 142: 321-346
    CrossrefPubMedGoogle Scholar
  • 6 Kalemkerian GP, Narula N, Kennedy EB. et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018; 36: 911-919
    CrossrefPubMedGoogle Scholar
  • 7 Zhang Y-L, Yuan J-Q, Wang K-F. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 29.11.2016; 7: 78985-78993
    CrossrefPubMedGoogle Scholar
  • 8 Ramalingam SS, Vansteenkiste J, Planchard D. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41-50
    CrossrefPubMedGoogle Scholar
  • 9 Leighl NB, Karaseva N, Nakagawa K. et al. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer 2020; 125: 49-57
    CrossrefPubMedGoogle Scholar
  • 10 Nakagawa K, Garon EB, Seto T. et al. Ramucirumab Plus Erlotinib in Patients With Untreated, EGFRmutated, Advanced Non-Small-Cell Lung Cancer (RELAY): A Randomised, Double-Blind, PlaceboControlled, Phase 3 Trial. Lancet Oncol 2019; 20: 1655-1669
    CrossrefPubMedGoogle Scholar
  • 11 Floc'h N, Martin MJ, Riess JW. et al. Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol Cancer Ther 2018; 17: 885-896
    CrossrefPubMedGoogle Scholar
  • 12 Janne PA, Neal JW, Camidge DR. et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. J Clin Oncol 05/2019; 37 (Suppl. 15) 9007-9007
    CrossrefPubMedGoogle Scholar
  • 13 Solomon BJ, Mok T, Kim D-W. et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N Engl J Med 2014; 371: 2167-2177
    CrossrefPubMedGoogle Scholar
  • 14 Camidge DR, Dziadziuszko R, Peters S. et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019; 14: 1233-1243
    CrossrefPubMedGoogle Scholar
  • 15 Camidge R, Kim HR, Ahn MJ. et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: updated results from the phase III ALTA-1L trial. Ann Oncol 2019; 30 (Suppl. 09) ix195-ix196
    CrossrefPubMedGoogle Scholar
  • 16 Camidge DR, Kim HR, Ahn MJ. et al. Brigatinib vs crizotinib in ALK-positive NSCLC. N Engl J Med 2018; 379: 2027-2039
    CrossrefPubMedGoogle Scholar
  • 17 Camidge DR, Kim HR, Ahn M-J. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018; 29: 2027-2039
    CrossrefPubMedGoogle Scholar
  • 18 Shaw AT, Felip E, Bauer TM. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 2017; 18: 1590-1599
    CrossrefPubMedGoogle Scholar
  • 19 Solomon BJ, Besse B, Tauer TM. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018; 19: 1654-1667
    CrossrefPubMedGoogle Scholar
  • 20 Mok T, Camidge DR, Gadgeel SM. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020; 31: 1056-1064
    CrossrefPubMedGoogle Scholar
  • 21 Shaw AT, Ou SH, Bang YJ. et al. Crizotinib in ROS-1 rearranged NSCLC. N Engl J Med 2014; 371: 1963-1971
    CrossrefPubMedGoogle Scholar
  • 22 Shaw A. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019; 30: 1121-1126
    CrossrefPubMedGoogle Scholar
  • 23 Drilon A, Siena S, Ou SI. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from phase I trails (ALKA-372-001 and STARTRK-1). Cancer Discov 2017; 7: 400-409
    CrossrefPubMedGoogle Scholar
  • 24 Shaw AT, Solomon BJ, Chiari R. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2019; 20: 1691-1701
    CrossrefPubMedGoogle Scholar
  • 25 Planchard D, Smit EF, Groen HJM. et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017; 18: 1307-1316
    CrossrefPubMedGoogle Scholar
  • 26 Planchard D, Besse B, Groen H. Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2020; 38: 9593
    CrossrefPubMedGoogle Scholar
  • 27 Paik PK, Arcila ME, Fara M. et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-2051
    CrossrefPubMedGoogle Scholar
  • 28 Drilon A, Oxnard GR, Tan DSW. et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383: 813-824
    CrossrefPubMedGoogle Scholar
  • 29 Wright KM. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC. Oncology (Williston Park) 2020; 34: 406-406; 431
    PubMedGoogle Scholar
  • 30 Stransky N, Cerami E, Schalm S. et al. The landscape of kinase fusions in cancer. Nat Commun 2014; 5: 4846
    CrossrefPubMedGoogle Scholar
  • 31 Drilon A, Laetsch TW, Kummar S. et al. Effiacy of larotrectinib in trk fusion-positive cancers in adults and chirldren. N Engl J Med 2018; 378: 731-739
    CrossrefPubMedGoogle Scholar
  • 32 Frampton GM, Ali SM, Rosenzweig M. et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015; 5: 850-859
    CrossrefPubMedGoogle Scholar
  • 33 Drilon A, Clark JW, Weiss J. et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020; 26: 47-51
    CrossrefPubMedGoogle Scholar
  • 34 Wolf J, Overbeck TR, Han J-Y. et al. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. J Clin Oncol 2020; 38
    PubMedGoogle Scholar
  • 35 Paik PK, Felip E, Veillon R. et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 2020; 383: 931-943
    CrossrefPubMedGoogle Scholar
  • 36 Arcila ME, Chaft JE, Nafa K. et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18: 4910-4918
    CrossrefPubMedGoogle Scholar
  • 37 Smit EF, Peters S, Dziadziuszko R. et al. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial. J Clin Oncol 2017; 35: 9070
    CrossrefPubMedGoogle Scholar
  • 38 Tsurutani J, Iwata H, Krop I. et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 2020; 10: 688-701
    CrossrefPubMedGoogle Scholar
  • 39 Smit EF, Nakagawa K, Nagasaka M. et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J Clin Oncol 2020; 38: 9504
    CrossrefPubMedGoogle Scholar
  • 40 Fakih M, O'Neil B, Price TJ. et al. Phase I study evaluating the safety, tolerability, pharmakocinetics (PK), and efficacy of AMG510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. J Clin Oncol 2019; 37: 3003
    CrossrefPubMedGoogle Scholar
  • 41 Govindan R, Fakih M, Price T. et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRASG12C inhibitor, evaluated in NSCLC. IASLC World Conference on Lung Cancer; 2018: abstr OA02.02.
    PubMedGoogle Scholar
  • 42 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Pembrolizumab vs chemotherapy for PD-L1-positive NSCLC. N Engl J Med 2016; 375: 1823-1833
    CrossrefPubMedGoogle Scholar
  • 43 Brahmer JulieR, Rodríguez-Abreu D, Robinson AG. et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 2017; 18: 1600-1609
    CrossrefPubMedGoogle Scholar
  • 44 Mok TSK, Wu YL, Kudaba I. et al. Pembrolizumab vs chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastaic NSCLC (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trail. Lancet 2019; 393: 1819-1830
    CrossrefPubMedGoogle Scholar
  • 45 Brahmer JR, Rodriguez-Abreu D, Robinson AG. et al. KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS)? 50%. . Annals of Oncology 2020; 31 (Suppl. 04) S1142-S1215
    CrossrefPubMedGoogle Scholar
  • 46 Paz-Ares L, Luft A, Vicente D. et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379: 2040-2051
    CrossrefPubMedGoogle Scholar
  • 47 Mazieres J, Kowalski D, Luft A. et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. J Clin Oncol 2020; 38: 271-280
    CrossrefPubMedGoogle Scholar
  • 48 Garassino MC, Gadgeel S, Esteban E. et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 387-397
    CrossrefPubMedGoogle Scholar
  • 49 West H, McCleod M, Hussein M. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-937
    CrossrefPubMedGoogle Scholar
  • 50 Socinski MA, Jotte RM, Cappuzzo F. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301
    CrossrefPubMedGoogle Scholar
  • 51 Reck M, Mok TSK, Nishio M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019; 7: 387-401
    CrossrefPubMedGoogle Scholar
  • 52 Gandhi L, Rodríguez-Abreu D, Gadgeel S. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 2078-2092
    CrossrefPubMedGoogle Scholar
  • 53 Hellmann MD, Paz-Ares L, Bemabe Caro R. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; 381: 2020-2031
    CrossrefPubMedGoogle Scholar
  • 54 Reck M, Ciuleanu T-E, Cobo Dols M. et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 9501-9501
    CrossrefPubMedGoogle Scholar
  • 55 Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
    CrossrefPubMedGoogle Scholar
  • 56 Borghaei H, Paz-Ares L, Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
    CrossrefPubMedGoogle Scholar
  • 57 Herbst RS, Baas P, Kim DW. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550
    CrossrefPubMedGoogle Scholar
  • 58 Herbst R, Garon E, Kim D-W. et al. OA03 07 KEYNOTE-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. . J Thoracic Oncol 2017; 12: S254-S255
    CrossrefPubMedGoogle Scholar
  • 59 Rittmeyer A, Barlesi F, Waterkamp D. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-265
    CrossrefPubMedGoogle Scholar
  • 60 Fehrenbacher L, von Pawel J, Park K. et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 2018; 13: 1156-1170
    CrossrefPubMedGoogle Scholar
  • 61 Felip Font E, Gettinger SN, Burgio MA. et al. Three-Year Follow-up From CheckMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology 2017; 28 (Suppl. 05) v460-v496 DOI: 10.1093/annonc/mdx380.
    CrossrefPubMedGoogle Scholar
  • 62 Herbst RS, Garon EB, Kim D-W. et al. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1? Positive, Advanced Non?Small-Cell Lung Cancer in the KEYNOTE-010 Study. . Journal of Clinical Oncology 2020; 38 : 1580-1590
    CrossrefPubMedGoogle Scholar